Log in

NASDAQ:CMTAClementia Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$26.35
0.00 (0.00 %)
(As of 04/17/2019)
Add
Compare
Today's Range
$26.28
Now: $26.35
$26.69
50-Day Range
$26.35
MA: $26.35
$26.35
52-Week Range
$8.10
Now: $26.35
$26.73
Volume716,706 shs
Average Volume145,059 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
Read More
Clementia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.18 per share

Profitability

Net Income$-58,130,000.00

Miscellaneous

Employees30
Market Cap$1.00 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) posted its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. View Clementia Pharmaceuticals' earnings history.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Media coverage about CMTA stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clementia Pharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutClementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

What other stocks do shareholders of Clementia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), JPMorgan Chase & Co. (JPM), Exelixis (EXEL), Eyepoint Pharmaceuticals (EYPT), Myokardia (MYOK), Rigel Pharmaceuticals (RIGL), Endocyte (ECYT), Amicus Therapeutics (FOLD) and Incyte (INCY).

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the following people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)
  • Mr. Jeffrey Packman, Chief Devel. Officer (Age 52)
  • Mr. Steve Forte, CFO & Corp. Sec. (Age 40)
  • Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $26.35.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $1.00 billion. The company earns $-58,130,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

What is Clementia Pharmaceuticals' official website?

The official website for Clementia Pharmaceuticals is www.clementiapharma.com.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.